患者由来異種移植片/PDXモデル市場：タイプ別、腫瘍タイプ別、研究タイプ別、移植方法別、用途別、エンドユーザー別-2025-2030年の世界予測

患者由来異種移植片/PDXモデル市場の2023年の市場規模は3億8,338万米ドルで、2024年には4億2,904万米ドルに成長し、CAGRは12.27%、2030年には8億6,231万米ドルに達すると予測されています。

患者由来の異種移植モデルという発展的な分野は、前臨床研究と医薬品開発のパラダイムを大きく変えてきました。ヒト腫瘍組織を免疫不全動物に移植するこの革新的なアプローチは、トランスレーショナル腫瘍学にとって不可欠なツールへと急速に発展しました。この手法は、ヒトの腫瘍微小環境を模倣する能力を高めており、その結果、治療効果や薬剤耐性を評価するための貴重なプラットフォームを提供するものとして尊敬を集めています。世界の動向が個別化医療へとますますシフトする中、PDXモデルは従来のin vitroシステムの限界を緩和するだけでなく、複雑ながん生物学に対するより深い洞察への道を開くものでもあります。本レポートでは、さまざまな用途でPDXモデルの採用を促進し続けている歴史的背景、基礎科学、市場力学を探求します。厳密な科学的探究と市場動向の洞察を融合させた詳細な分析により、読者はPDXモデルの複雑なニュアンスを理解することができます。包括的な研究データと分析的フレームワークの統合により、専門家や意思決定者は、既存の課題と新たな機会をしっかりと理解することができ、この革新的な生物医学研究分野への継続的な革新と投資の舞台を整えることができます。

患者由来異種移植片/PDXモデル市場の変革

近年、技術革新、進化する規制の枠組み、より予測性の高い前臨床試験モデルに対する着実な需要によって、PDXモデル市場に変革的な変化が起きています。この変化は、従来の細胞株ベースのモデルの欠点と、ヒト腫瘍生物学を忠実に再現するシステムの切実な必要性が認識されるようになったことに根ざしています。遺伝子工学とイメージング技術の進歩により、PDX研究の精度と再現性がさらに強化され、複雑な腫瘍学の課題を克服するための体制が学術的、産業的研究ともに整ってきています。

市場のプレーヤーは、高度なデータ解析とリアルタイムのモニタリングを組み合わせた統合プラットフォームを活用しており、治療反応に関するこれまでにない洞察を提供しています。実験ワークフローを合理化して所要時間とコストを削減することに重点が置かれ、その結果、新たながん種や治療法への機敏な対応が促進されています。研究者が個々の患者のプロファイルに合わせて治療法を調整しようと絶えず努力しているため、市場は個別化医療へと大きく舵を切っています。このシフトは、前臨床評価においてより高い精度を要求するだけでなく、研究機関、バイオテクノロジー企業、規制当局間の強固な協力関係を必要とし、最終的にはがん研究と医薬品開発の新たな基準を打ち立てることになります。

包括的な主要セグメントに関する洞察

PDXモデル市場のセグメンテーションにより、現在の業界動向に関する実用的な洞察を提供する明確なパターンが明らかになりました。種類に基づく分析では、マウスモデルとラットモデルを区別し、それぞれの動物系に関連するニュアンスと特定の利点を強調します。腫瘍の種類というレンズを通すと、消化器がん、婦人科がん、血液がん、呼吸器がん、泌尿器がんなど、多様ながんが調査対象となり、臨床像に内在する異質性に対応することができます。調査手法のセグメント化には、生体外、生体内、生体内の各手法が含まれ、それぞれヒトの生物学的反応をシミュレートする際に独自の強みを発揮します。さらに、移植方法に基づいてモデルを区別することで、実験結果の妥当性と精度を高める上で、異所性、同所性、皮下アプローチが重要であることがわかる。

市場内の用途も同様に多様で、基礎的がん研究、バイオマーカー探索、ゲノム・分子研究、個別化医療、前臨床薬物評価、腫瘍微小環境解析に及んでいます。学術研究機関、がん研究センター、製薬・バイオテクノロジー企業はそれぞれ、これらのモデルの試験、検証、最終的な臨床応用において重要な役割を担っています。このような多面的なセグメンテーションアプローチは、このダイナミックな分野における研究コミュニティの専門性の深さと相互関連性を強調するものです。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の上昇により、創薬を促進するための高度な前臨床モデルの必要性が高まっている
    • 腫瘍学調査に対する政府の取り組みと資金の増加
    • 患者転帰の向上を目指した精密医療へのPDXモデルの導入
  • 抑制要因
    • PDXモデルの不安定性と高コストの影響に関する懸念
  • 機会
    • がん治療薬開発を加速するための戦略的連携とパートナーシップ
    • 薬物検査における高度な分析プラットフォームとPDXモデルの統合
  • 課題
    • 調査における患者由来異種移植モデルの使用を制限する倫理的懸念と規制
• 市場セグメンテーション分析
  • タイプ：遺伝的類似性がトランスレーショナル腫瘍学調査におけるマウスモデルの役割を強化する
  • 腫瘍の種類：PDXモデルは遺伝的および表現型の面でヒトの疾患を厳密に模倣できるため、血液がんでの使用が増加しています。
  • 研究タイプ：ヒト腫瘍生物学の正確な再現を通じて前臨床がん調査を強化する生体内モデル
  • 移植方法：皮下移植の採用が増加している理由は、調査現場でのその簡便性と実用性によるものです。
  • アプリケーション：正確ながんシミュレーションによる前臨床薬剤評価を促進するPDXモデル
  • エンドユーザー：製薬企業およびバイオテクノロジー企業における患者由来異種移植/PDXモデルを用いた医薬品開発のイノベーションの推進
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 患者由来異種移植片/PDXモデル市場：タイプ別

• マウスモデル
• ラットモデル

第7章 患者由来異種移植片/PDXモデル市場腫瘍の種類別

• 胃腸
• 婦人科
• 血液学
• 呼吸器
• 泌尿器科

第8章 患者由来異種移植片/PDXモデル市場研究タイプ別

• 生体外
• 体外
• 生体内

第9章 患者由来異種移植片/PDXモデル市場移植方法別

• 異所性
• 正所性
• 皮下

第10章 患者由来異種移植片/PDXモデル市場：用途別

• ファンデーションがん調査
• バイオマーカーの発見
• ゲノムおよび分子研究
• パーソナライズ医療
• 前臨床薬物評価
• 腫瘍微小環境解析

第11章 患者由来異種移植片/PDXモデル市場：エンドユーザー別

• 学術調査機関
• がん研究センター
• 製薬・バイオテクノロジー企業

第12章 南北アメリカの患者由来異種移植片/PDXモデル市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の患者由来異種移植片/PDXモデル市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの患者由来異種移植片/PDXモデル市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abnova Corporation
• Altogen Labs
• Biocytogen
• BioDuro LLC
• BioReperia AB
• Certis Oncology Solutions
• Champions Oncology, Inc.
• Charles River Laboratories International, Inc.
• Creative Animodel
• Creative Biolabs
• Crown Bioscience by JSR Corporation
• EPO Berlin-Buch GmbH
• GemPharmatech Co. Ltd.
• Genesis Drug Discovery & Development
• Hera Biolabs
• HOIST Co.,Ltd.
• InnoSer
• Inotiv, Inc.
• Laboratory Corporation of America Holdings
• LIDE Shanghai Biotech, Ltd
• Mediford Corporation by PHC Holdings Corporation
• Oncodesign Services
• Shanghai ChemPartner
• Shanghai Medicilon Inc.
• TheraIndx Lifesciences Pvt. Ltd.
• Urosphere SAS
• WuXi AppTec Co., Ltd.
• Xentech

LIST OF FIGURES

• FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-CURRENCY
• FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-LANGUAGE
• FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
• FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 23. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 29. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
• TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 286. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

The Patient-Derived Xenograft/PDX Model Market was valued at USD 383.38 million in 2023 and is projected to grow to USD 429.04 million in 2024, with a CAGR of 12.27%, reaching USD 862.31 million by 2030.

The evolving field of patient-derived xenograft models has significantly reshaped preclinical research and drug development paradigms. This innovative approach, which involves implanting human tumor tissues into immunocompromised animals, has swiftly developed into a vital tool for translational oncology. The methodology is gaining respect for its enhanced ability to mimic the human tumor microenvironment, thereby providing an invaluable platform for evaluating therapeutic efficacy and drug resistance. As global healthcare trends increasingly shift towards personalized medicine, PDX models not only mitigate the limitations of traditional in vitro systems but also pave the way for deeper insights into complex cancer biology. This report explores the historical context, underlying science, and market dynamics that continue to drive the adoption of these models across a range of applications. Detailed analyses that blend rigorous scientific inquiry with market trend insights guide readers through the intricate nuances of PDX models. The integration of comprehensive research data and analytical frameworks provides experts and decision-makers with a robust understanding of existing challenges and emerging opportunities, setting the stage for continued innovation and investment in this transformative area of biomedical research.

Transformative Shifts in the PDX Model Market Landscape

Recent years have seen transformative shifts in the PDX model market driven by technological innovation, evolving regulatory frameworks, and the steady demand for more predictive preclinical testing models. This transformation is rooted in the increasing recognition of the shortcomings of conventional cell-line based models and the compelling need for systems that closely replicate human tumor biology. Progressive advancements in genetic engineering and imaging technologies have further bolstered the precision and reproducibility of PDX studies, ensuring that both academic and industrial research avenues are well-equipped to navigate complex oncology challenges.

Market players are capitalizing on integrated platforms that combine advanced data analytics with real-time monitoring, offering unprecedented insights into therapeutic responses. There is a pronounced emphasis on streamlining experimental workflows to reduce turnaround time and cost, which in turn fosters a more agile response to emerging cancer types and treatment modalities. As researchers continually strive to tailor therapies to individual patient profiles, the market is experiencing a profound pivot towards personalized medicine. This shift not only demands higher accuracy in preclinical evaluation but also necessitates robust collaboration between research institutions, biotechnology companies, and regulatory bodies, ultimately setting a new standard for cancer research and drug development.

Comprehensive Key Segmentation Insights

The segmentation of the PDX model market reveals distinct patterns that offer actionable insights into current industry trends. An analysis based on type differentiates between mice models and rat models, highlighting the nuances and specific advantages associated with each animal system. When viewed through the lens of tumor type, research encompasses a diverse range that includes gastrointestinal, gynecological, hematological, respiratory, and urological cancers, thereby addressing the heterogeneity inherent in clinical presentations. The study type segmentation covers ex-vivo, in-vitro, and in-vivo methodologies, each providing unique strengths when it comes to simulating human biological responses. Furthermore, distinguishing models based on the implantation method shows the importance of heterotopic, orthotopic, and subcutaneous approaches in refining the relevance and accuracy of experimental outcomes.

Applications within the market are equally diverse, spanning basic cancer research, biomarker discovery, genomic and molecular studies, personalized medicine, preclinical drug evaluation, and tumor microenvironment analysis. End-user segmentation adds another important layer of insight, with academic research institutes, cancer research centers, and pharmaceutical and biotechnology companies each playing critical roles in the testing, validation, and eventual clinical translation of these models. Such a multifaceted segmentation approach underscores the depth of specialization and the interconnected nature of the research community in this dynamic field.

Based on Type, market is studied across Mice Models and Rat Models.

Based on Tumor Type, market is studied across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological.

Based on Study Type, market is studied across Ex-vivo, In-vitro, and In-vivo.

Based on Implantation Method, market is studied across Heterotopic, Orthotopic, and Subcutaneous.

Based on Application, market is studied across Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis.

Based on End-User, market is studied across Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies.

Regional Insights Supporting Global Market Trends

Geographical analysis of the PDX model market illustrates a robust, multi-regional growth narrative with significant contributions emerging from several key territories. In the Americas, robust investment in biomedical research infrastructure and supportive governmental policies continue to drive advancements. Meanwhile, regions encompassing Europe, the Middle East and Africa are increasingly prioritizing translational research, with a greater alignment towards personalized treatment approaches and more stringent regulatory oversight supporting higher quality preclinical evaluations. Asia-Pacific stands out as a vibrant hub of innovation, supported by substantial investment in biotechnology and an expanding base of both clinical and academic research institutions. The convergence of these regional dynamics not only creates a fertile ground for collaborative research but also reinforces global standards through data sharing and cross-border partnerships.

Collectively, these regional insights point to a future where market expansion will be bolstered by a unified approach to research excellence. The confluence of diverse regional capabilities ensures that the benefits of PDX models are realized on a global scale, thereby supporting a more integrated and responsive healthcare system worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Analysis of Leading Market Players

The competitive landscape in the PDX market is defined by a robust roster of companies that continue to push the boundaries of preclinical research and drug development. Key market players include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech.

These organizations have strategically capitalized on technological innovations and deep scientific expertise to address an increasingly competitive market environment. Their ongoing investments in research and development, persistent focus on quality and scalability, and commitment to forging strategic collaborations have been pivotal in expanding their respective portfolios. By maintaining a forward-thinking approach, these leaders ensure that their platforms remain at the cutting edge, thereby contributing significantly to the evolution of preclinical cancer research. Their efforts not only drive market growth but also inspire emerging players to adopt more rigorous standards in the pursuit of clinical excellence.

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech. Actionable Recommendations for Industry Leaders

For industry leaders looking to harness the potential of PDX models, several actionable strategies emerge from current market trends. Optimizing research pipelines by investing in state-of-the-art imaging, genetic profiling, and data integration tools can significantly enhance preclinical validation and streamline drug development processes. Enhancing collaborative networks with leading academic institutions and clinical research centers will also be crucial in accessing real-world insights and accelerating translational research.

It is recommended that companies invest in robust quality control measures and standardization protocols to increase the reproducibility and reliability of their models. Broadening the spectrum of tumor types and refining implantation methodologies can further boost the clinical relevance of studies, thereby offering more targeted insights for personalized medicine initiatives. Leaders should also consider strategic partnerships and joint ventures as pivotal avenues for expanding their technological capabilities and accessing untapped markets. Finally, a dedicated focus on regulatory intelligence will enable organizations to navigate evolving legal frameworks more effectively, ensuring seamless integration of innovative approaches within established clinical paradigms.

Conclusion and Forward-Looking Perspective

In summing up, the landscape of patient-derived xenograft models represents a transformative and dynamic segment within the broader realm of oncology research and drug development. The integration of advanced biological models with cutting-edge technologies has paved the way for an era where preclinical assessments are more predictive and clinically relevant than ever before. This evolution not only underscores the importance of PDX models as a cornerstone for modern cancer research but also points to a future marked by enhanced precision, greater personalization, and more rapid translational outcomes.

As the market continues to evolve, stakeholders across academia, industry, and regulatory agencies must embrace the opportunities born of this convergence. A concerted effort in addressing experimental challenges, fine-tuning methodological approaches, and fostering strategic research partnerships will be key to unlocking further advancements. The journey ahead promises exciting developments, laying a robust foundation for innovations that are set to redefine therapeutic paradigms and ultimately improve patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in cancer prevalence amplifying the need for advanced preclinical models to enhance drug discovery
    • 5.1.1.2. Increased government initiatives and fundings for oncology research
    • 5.1.1.3. Incorporation of PDX models in precision medicine for enhanced patient outcomes
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with instability and high-cost implications of PDX models
  • 5.1.3. Opportunities
    • 5.1.3.1. Strategic collaborations and partnership to accelerate cancer drug development
    • 5.1.3.2. Integration of advanced analytical platforms with PDX models in drug testing
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical concerns and regulations limiting the use of patient-derived xenograft models in research
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Genetic similarity enhances mice model's role in translational oncology research
  • 5.2.2. Tumor Type: The ability of PDX models to closely mimic the human disease in genetic and phenotypic aspects increases the usage in hematological cancers
  • 5.2.3. Study Type: In-vivo Models enhancing preclinical cancer research through accurate replication of human tumor biology
  • 5.2.4. Implantation Method: The increasing adoption of subcutaneous implantation is driven by its simplicity and practicality in research settings
  • 5.2.5. Application: PDX models advancing preclinical drug evaluation with accurate cancer simulation
  • 5.2.6. End-User: Driving innovation in drug development with Patient-Derived Xenograft/PDX models in pharmaceutical and biotechnology companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

• 6.1. Introduction
• 6.2. Mice Models
• 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 7.1. Introduction
• 7.2. Gastrointestinal
• 7.3. Gynecological
• 7.4. Hematological
• 7.5. Respiratory
• 7.6. Urological

8. Patient-Derived Xenograft/PDX Model Market, by Study Type

• 8.1. Introduction
• 8.2. Ex-vivo
• 8.3. In-vitro
• 8.4. In-vivo

9. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

• 9.1. Introduction
• 9.2. Heterotopic
• 9.3. Orthotopic
• 9.4. Subcutaneous

10. Patient-Derived Xenograft/PDX Model Market, by Application

• 10.1. Introduction
• 10.2. Basic Cancer Research
• 10.3. Biomarker Discovery
• 10.4. Genomic & Molecular Studies
• 10.5. Personalized Medicine
• 10.6. Preclinical Drug Evaluation
• 10.7. Tumor Microenvironment Analysis

11. Patient-Derived Xenograft/PDX Model Market, by End-User

• 11.1. Introduction
• 11.2. Academic Research Institutes
• 11.3. Cancer Research Centers
• 11.4. Pharmaceutical & Biotechnology Companies

12. Americas Patient-Derived Xenograft/PDX Model Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Certis Oncology unveils AI-driven chatbot to enhance cancer research insights and PDX model efficiency
  • 15.3.2. UCLB and CancerTools.org partnership enhances new NSCLC PDX models development
  • 15.3.3. Champions Oncology announces licensing agreement with Weill Cornell Medicine
  • 15.3.4. REM-422 demonstrates tumor regression in ACC PDX models at 2024 symposium
  • 15.3.5. Charles River Laboratories transforming oncology research with PDX models and digital twins at AACR 2024
  • 15.3.6. Crown Bioscience has announced new preclinical and translational oncology data at the AACR 2024
  • 15.3.7. ProteinQure unveils breakthrough PDC showcasing exceptional efficacy in diverse PDX models
  • 15.3.8. InVivo Biosystems and BioReperia partners to transform cancer drug development
  • 15.3.9. Kiyatec and XenoSTART collaborated to help reduce drug development costs
  • 15.3.10. Soteria Precision Medicine Foundation partners with Certis Oncology Solutions
• 15.4. Strategy Analysis & Recommendation
  • 15.4.1. WuXi AppTec Co., Ltd.
  • 15.4.2. Crown Bioscience by JSR Corporation
  • 15.4.3. Mediford Corporation by PHC Holdings Corporation
  • 15.4.4. Charles River Laboratories International, Inc.

Companies Mentioned

• 1. Abnova Corporation
• 2. Altogen Labs
• 3. Biocytogen
• 4. BioDuro LLC
• 5. BioReperia AB
• 6. Certis Oncology Solutions
• 7. Champions Oncology, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. Creative Animodel
• 10. Creative Biolabs
• 11. Crown Bioscience by JSR Corporation
• 12. EPO Berlin-Buch GmbH
• 13. GemPharmatech Co. Ltd.
• 14. Genesis Drug Discovery & Development
• 15. Hera Biolabs
• 16. HOIST Co.,Ltd.
• 17. InnoSer
• 18. Inotiv, Inc.
• 19. Laboratory Corporation of America Holdings
• 20. LIDE Shanghai Biotech, Ltd
• 21. Mediford Corporation by PHC Holdings Corporation
• 22. Oncodesign Services
• 23. Shanghai ChemPartner
• 24. Shanghai Medicilon Inc.
• 25. TheraIndx Lifesciences Pvt. Ltd.
• 26. Urosphere SAS
• 27. WuXi AppTec Co., Ltd.
• 28. Xentech